tv.qiagenbioinformatics.com

How decentralized and small labs can adopt high-throughput NGS analysis with...

Fri, 14 Jun 2024 23:53:55 GMT

Next-generation sequencing (NGS) has rapidly gained popularity as a diagnostic testing approach due to its unparalleled ability to comprehensively analyze genetic information with high throughput and precision. However, decentralized and small labs face significant hurdles when it comes to adopting NGS testing. From high upfront costs associated with acquiring the necessary equipment, to the complexity of bioinformatics tools and compliance management that require specialized expertise in data analysis and data security, adopting NGS poses challenges for labs with limited staff and infrastructure.

To empower small and decentralized labs to easily adopt NGS testing, QIAGEN has launched a new secondary analysis solution for oncology and inherited disease applications that enables high-throughput secondary analysis for use with any clinical NGS data. In this webinar, learn about QCI Secondary Analysis, an agnostic, cloud-based software-as-a-service (SaaS) solution that seamlessly integrates with QCI Interpret, QIAGEN’s clinical variant interpretation and reporting software, to deliver highly scalable and customizable Sample to Insight workflows for oncology and inherited disease applications.

In this webinar, attendees will learn how QCI Secondary Analysis:

. Streamlines analysis from a range of assay types, enabling labs to process more sequencing data without extensive time and resource investment.
. Ensures the highest degree of isolation and data protection, including compliance with ISO 27001, General Data Protect Regulation (GDPR), and the Health Insurance Portability and Accountability Act (HIPPA) requirements.
. Directly connects to QCI Interpret for an integrated and automated FASTQ-to-report workflow with limited hands-on time.

Lower the barrier to adopt larger CGP in Dx labs: QIAGEN Expert Talks in US

Fri, 27 May 2022 17:55:59 GMT

A two-part event, the Break the Data Bottleneck Summit will explore how small to mid-sized clinical diagnostic labs can compete to offer comprehensive genomic profiling services for precision oncology with the same speed and confidence of large hospital networks and university centers.

Featured topics at the event include:

Expert tips to improve the accuracy and efficiency of your molecular tumor boards
How to accelerate your bioinformatics pipeline from FASTQ to report
How your lab can stay up-to-date on guidelines, therapies, and clinical trials

Part 1: May 19, 2022 (Americas and Europe)

QIAGEN Expert Talks

Part 2: June 16, 2022 (Americas) and June 21, 2022 (Europe)

Customer Insights

Identify meaningful mutations in somatic tumor testing

Mon, 14 Feb 2022 14:54:55 GMT

From Information Overload to Actionable Insights

Precision medicine is transforming cancer care, with next-generation sequencing (NGS) enabling the simultaneous analysis of multiple genomic alterations with therapeutic implications. However, due to the sporadic nature of somatic cancers and the increasing uptake of NGS testing, the number of detected variants is exponentially growing, challenging labs to confidently identify meaningful mutations that could influence or improve decisions at the point of care. Approximately 50 percent of the oncologists in the United States find NGS results sometimes or often difficult to interpret, while 31 percent of small to medium-sized labs in Europe view a lack of knowledge and exposure to routine analyses and interpretation as the most critical bottleneck in NGS testing [1-2].

In this webinar, Ana Krivokuca will present a real-world use case of how the Institute for Oncology and Radiology of Serbia (IORS), a national cancer research center that provides routine NGS testing for cancer patients, uses the Human Somatic Mutation Database (HSMD) in their NGS testing pipeline to validate, assess, and better understand the clinical significance of detected variants.

A new somatic database from QIAGEN, HSMD combines two decades of expert-curated content with data from over 300,000 real-world clinical oncology cases to provide deep genomic insight into the molecular characterizations of a patient’s tumor. Easy to search with new content added weekly, HSMD enables users to explore key genes or mutations with driving properties or clinical relevance, search for associated treatment options, evaluate secondary findings, and develop customized gene panels.

Attendees will:

Learn how IORS uses HSMD to identify actionable variants, analyze complex reports, evaluate secondary findings, and design custom gene panels.
Explore HSMD content and features through a virtual demonstration.
Receive a complimentary, five-day trial of HSMD.

Speaker:
Ana Krivokuca, PhD
Head of Department for Genetic Counseling
Institute for Oncology and Radiology of Serbia

Get expert variant classification services tailored to your onco-panel

Thu, 09 Dec 2021 07:22:05 GMT

As next-generation DNA sequencing technology continues to evolve and become further integrated into routine clinical testing, the need for efficient and accurate clinical interpretation of oncology diagnostic tests becomes even more pressing—especially among community hospital labs.

Standard sequencing panels are growing, drugs are covering more targets and pathways, and the expansion of the scientific and clinical literature has become exponential, presenting a significant challenge to laboratory directors and clinicians who need to understand the implications of the test results. Further, the implications of mutations can be applicable across many cancer types, but often are different based on the specific cancer type.

In this webinar, we will discuss how community hospital labs can perform comprehensive genomic profiling faster and with greater accuracy and confidence using QIAGEN’s professional clinical interpretation services: QCI Precision Insights.

Attendees will learn:

About the world-class team of molecular biologists and oncologists that power QCI Precision Insights
How community hospital labs can get up-to-date and detailed disease-specific clinical insights and therapeutic options for each patient within minutes
About use-cases and examples of clinical annotation in different diseases of varying specificity

Speakers
Sheryl Elkin, PhD
Chief Scientific Officer
N-of-One, a QIAGEN company

Linda Call, Ph.D.
Director of Scientific and Clinical Operations
QIAGEN Digital Insights

Variant Calling to Biological Insights – A Lynch Syndrome Case Study

Thu, 09 Dec 2021 07:19:18 GMT

In this webinar, we present a case study on Lynch syndrome (LS), a hereditary condition characterized by a high risk of colorectal cancer, endometrial cancer, and other neoplasia that typically manifests in the context of germline variants in DNA mismatched genes.
To study whether other germline pathogenic variants of hereditary cancer genes are present in patients previously diagnosed with LS, the researchers analyzed a comprehensive panel of cancer-predisposing genes by NGS among 84 LS probands.

With this study as an example, we will illustrate how you can use your own data and public data to conduct translational research using 3 software solutions from QIAGEN.

This webinar will focus on the following elements:

Data analysis – How you can efficiently retrieve and process FASTQ data with accurate variant interpretation using CLC Genomics Workbench
Interpretation – How you can take a set of variants and rapidly assess sample variants for disease relevance and pathogenicity using QCI Interpret Translational
Discovery – How you can combine results and contextualize variant biomarkers with other public datasets using QIAGEN Ingenuity Pathway Analysis (IPA)

Speaker:

Eric Seiser, PhD
Senior Field Applications Scientist
QIAGEN Digital Insights